FAST III was initiated five years ago to evaluate whether revascularization guided by angiography–based FFR using CAAS vFFR (vessel Fractional Flow Reserve) delivers therapeutic outcomes comparable to ...

Non-inferiority trials have become an essential instrument in clinical research, particularly when the goal is to demonstrate that an experimental treatment is not unacceptably worse than an ...

ONS-5010 shows non-inferiority to Lucentis at 12 weeks; BLA resubmission planned for Q1 2025, with $20.4M in proceeds expected. ONS-5010 demonstrated non-inferiority to ranibizumab at week 12, ...

Ultrahypofractionated radiotherapy demonstrated non-inferiority to conventional fractionation with higher 10-year failure-free survival with similar toxicity profiles in patients with intermediate- or ...

Large randomized trial makes case for non-inferiority versus surgery; smaller study falls ...

(RTTNews) - Outlook Therapeutics, Inc. (OTLK), a biopharmaceutical company, on Thursday announced the completion of the 12-week efficacy and safety results from its NORSE EIGHT clinical trial for ...

Please provide your email address to receive an email when new articles are posted on . Noninferiority trials test whether a new treatment is not less efficacious than an already approved therapy.

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Study from New Zealand was of particular benefit to Mori and under-screened women ...

Today at the American College of Cardiology's Annual Scientific Session (ACC.26) taking place in New Orleans, Louisiana, Dr. Ajay J. Kirtane from New York-Presbyterian/Columbia University Irving ...